{"id":"deferiprone-sustained-release","phase":"phase_1","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":["Nausea","Vomiting","Abdominal pain","Chromaturia (reddish-brown urine)","Arthralgia"],"contraindications":["Neutropenia","Hypersensitivity to deferiprone"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT02189941"],"aliases":["Deferiprone"],"patents":[],"pricing":[],"modality":"Small molecule","timeline":[],"aiSummary":"","brandName":"Deferiprone sustained-release","companyId":"apopharma","mechanism":{"target":"Ferric iron (Fe3+)","novelty":"","modality":"Small molecule","drugClass":"","explanation":"Deferiprone is a bidentate iron chelator that binds to free iron in a 3:1 molar ratio. By forming stable, water-soluble complexes with ferric ions, it facilitates iron removal from the body through urinary excretion, reducing iron accumulation in tissues and organs.","oneSentence":"Deferiprone chelates excess iron by binding to ferric ions, forming stable complexes that are excreted primarily in urine.","technicalDetail":""},"commercial":null,"_claudeStub":{"ts":1779123387,"model":"claude-sonnet-4-5-20250929"},"companyName":"ApoPharma","competitors":[{"name":"Deferasirox","brand":"Exjade","company":"Novartis","rationale":"Once-daily oral iron chelator for transfusional iron overload"},{"name":"Deferoxamine","brand":"Desferal","company":"Novartis","rationale":"Parenteral iron chelator for chronic iron overload conditions"},{"name":"Deferiprone immediate-release","brand":"Ferriprox","company":"ApoPharma","rationale":"Original formulation requiring multiple daily doses"}],"description":"Deferiprone sustained-release is a modified formulation of deferiprone, an oral iron chelator being developed by ApoPharma. This sustained-release version aims to improve dosing convenience and potentially reduce side effects compared to immediate-release deferiprone in patients with iron overload conditions.","genericName":"Deferiprone sustained-release","indications":{"approved":[{"status":"investigational","condition":"Transfusional iron overload","patientPopulation":"Adult and paediatric patients"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}